A phase Ib clinical trial of TIDAL-01 in solid tumors, including cutaneous and non-cutaneous melanoma
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs TIDAL-01 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 04 Feb 2025 Status changed from planning to discontinued.
- 01 Sep 2023 According to a Turnstone Biologics media release, company expects to provide an initial clinical update in mid-2024.
- 06 Jul 2022 According to a Turnstone Biologics media release, this trial is expected to commence later this year